ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för narlaprevir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2021-02-04

Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening.

Manandhar A, Blass BE, Colussi DJ, Almi I, Abou-Gharbia M, Klein ML, Elokely KM.

J Chem Inf Model · journal article · DOI 10.1021/acs.jcim.0c01457

Bibliografisk träff 2021-02-04

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.

Bai Y, Ye F, Feng Y, Liao H, Song H, Qi J, Gao GF, Tan W, Fu L, Shi Y.

Signal Transduct Target Ther · letter; research support, non-u.s. gov't · DOI 10.1038/s41392-021-00468-9

Bibliografisk träff 2021-02-01

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.

Baker JD, Uhrich RL, Kraemer GC, Love JE, Kraemer BC.

PLoS One · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1371/journal.pone.0245962

Bibliografisk träff 2020-10-23

Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals.

Kneller DW, Galanie S, Phillips G, O'Neill HM, Coates L, Kovalevsky A.

Structure · comment; brief-report; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.str.2020.10.007

Bibliografisk träff 2019-08-15

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

Klimova EA, Burnevich EZ, Chulanov VP, Gusev DA, Znoyko OO, Batskikh SN, Kizlo SN, Mamonova NA, Tarkhova EP, Krasavina EN, Samsonov MY, Yushchuk ND.

Ter Arkh · clinical trial; journal article · DOI 10.26442/00403660.2019.08.000384

Bibliografisk träff 2016-11-21

Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.

Isakov V, Koloda D, Tikhonova N, Kikalishvili T, Krasavina E, Lekishvili K, Malaya I, Ryska M, Samsonov M, Tolkacheva V.

Antimicrob Agents Chemother · controlled clinical trial; research-article; clinical trial, phase i; journal article · DOI 10.1128/aac.01044-16

Bibliografisk träff 2014-07-23

Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.

Wang H, Geng L, Chen BZ, Ji M.

Biochem Cell Biol · research support, non-u.s. gov't; journal article · DOI 10.1139/bcb-2014-0039

Bibliografisk träff 2013-06-27

Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.

de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J.

J Viral Hepat · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/jvh.12104

Bibliografisk träff 2013-01-07

Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.

Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HL, Reesink HW.

J Viral Hepat · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/jvh.12012

Bibliografisk träff 2012-07-01

Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.

Zhu J, Li Y, Yu H, Zhang L, Mao X, Hou T.

Comb Chem High Throughput Screen · research support, non-u.s. gov't; journal article · DOI 10.2174/138620712800563918

Bibliografisk träff 2011-06-20

Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.

Gao L, Li J, Kasserra C, Song Q, Arjomand A, Hesk D, Chowdhury SK.

Anal Chem · evaluation study; journal article · DOI 10.1021/ac2006284

Bibliografisk träff 2010-11-01

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.

de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ.

Hepatology · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/hep.23899

Bibliografisk träff 2010-03-22

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.00135-10

Bibliografisk träff 2010-02-15

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Arasappan A, Bennett F, Bogen SL, Venkatraman S, Blackman M, Chen KX, Hendrata S, Huang Y, Huelgas RM, Nair L, Padilla AI, Pan W, Pike R, Pinto P, Ruan S, Sannigrahi M, Velazquez F, Vibulbhan B, Wu W, Yang W, Saksena AK, Girijavallabhan V, Shih NY, Kong J, Meng T, Jin Y, Wong J, McNamara P, Prongay A, Madison V, Piwinski JJ, Cheng KC, Morrison R, Malcolm B, Tong X, Ralston R, Njoroge FG.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml9000276

Bibliografisk träff 2010-01-01

[Inhibitors of hepatitis C virus--therapeutic possibilities].

Godzik P, Komorowski M, Cielecka-Kuszyk J, Madaliński K.

Przegl Epidemiol · journal article; english abstract

Gå till forskningen.

Publikationer i urvalet

Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: <i>In Silico</i> Modeling and <i>In Vitro</i> Screening.

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.

Malleability of the SARS-CoV-2 3CL M<sup>pro</sup> Active-Site Cavity Facilitates Binding of Clinical Antivirals.

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.

Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.

Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.

Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.

Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.

Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

[Inhibitors of hepatitis C virus--therapeutic possibilities].